Danaher Diagnostics A.I CyberSecurity Scoring
22/02/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Danaher Diagnostics in 2026.
No incidents recorded for Danaher Diagnostics in 2026.
No incidents recorded for Danaher Diagnostics in 2026.
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We advance our mission to alleviate pain and improve the quality of life for patients around the world with our innovative products and suite of integrated digital and robotic technologies leverage data, data analytics and artificial intelligence. Founded in 1927 and based in Warsaw, Zimmer Biomet has operations in more than 25 countries and sales in more than 100 countries. We maintain world-class scientific facilities and resources and collaborate with leading clinicians and researchers around the world. Awards and Recognitions • Forbes: America's Best Companies 2026 • Workhuman: Luminary Award 2025 & Innovator Award 2024 • TIME: America's Best Companies [Mid-Size] 2024 • Great Place to Work - Best Workplaces: Switzerland & Poland 2025 • Great Place to Work Certified 2025 - 2026: USA, Poland, India, Colombia, Ireland, Puerto Rico, Kingdom of Saudi Arabia, Switzerland • MedTech: Breakthrough Award Best New Technology Solution in Orthopedics 2025 • Top Employers Institute: China 2025 • VETS Indexes: 4 Star Employer 2025
For nearly a century, we have delivered on our commitment to saving and sustaining the lives of patients, working alongside clinicians and providers around the world. We believe every person — regardless of who they are or where they are from — deserves a chance to live a healthy life, free from illness and full of possibility. At the intersection of progress and purpose is where we are redefining what it means to be a global medtech leader. It is where we are relentlessly pursuing healthcare transformation, fueled by our compassion for patients and providers and the challenges they face. It is where bold ideas meet the promise for meaningful change in the world around us. We are there, at every step of the journey, to help clinicians deliver the best care possible.
As a leading medical technology company, B. Braun protects and improves the health of people around the world. For more than 185 years, the family-owned company has been accelerating progress in health care with pioneering spirit and groundbreaking contributions. This innovative strength continues to be the foundation of B. Braun's success today—always with the goal of improving clinical outcomes, cost of care and patient benefits. More than 64,000 employees live Sharing Expertise worldwide, they make B. Braun a true partner that develops integrated solutions and sets new standards. By linking products, services and consulting, the company improves treatment processes and supports medical staff. In doing so, B. Braun always acts with future generations in mind, which is why responsibility for sustainable growth is embedded into all business processes. In 2024, the B. Braun Group generated sales of € 9.1 billion. Imprint: https://www.bbraun.com/en/imprint.html Privacy Policy: https://www.bbraun.com/en/privacy-policy.html
Smith+Nephew is a global medical technology company. We design and manufacture technology that takes the limits off living. We support healthcare professionals to return their patients to health and mobility, helping them to perform at their fullest potential. From our first employee and founder, T.J. Smith, to our team today, it’s our people who make Smith+Nephew a unique place. Yes, we love to innovate and develop exciting technologies, and we offer competitive salaries and progressive benefits. But it’s our culture - of Care, Collaboration and Courage - that really sets us apart. Through a spirit of ownership and can-do attitude, we work together to win.. We’re a company of people who care about each other, about our customers and their patients, and about our communities. Together, we fulfill our shared purpose of Life Unlimited. Please note: not all products referred to may be approved for use or available in all markets.
We are dedicated to transforming lives by improving the journey to a healthy, beautiful smile. Discover your straight path to a bright future at Align Technology. As a part of our smart, diverse and fast-moving global team, you'll make an impact on the market leader that's moving an industry forward. Want to find out what's next for us—and for you? Follow us on LinkedIn for business updates and check out our current opportunities at www.aligntech.com/careers. 25 years ago, we pioneered the market for clear aligners. Since then, we have continuously innovated with new products and technologies that revolutionize treatments for doctors and their patients. Today, doctors and labs in over 100 markets use the Invisalign system, iTero intraoral scanners and exocad software to improve smiles for patients – from simple tooth alignment to complex corrections, kids to adults, orthodontics to multi-disciplinary restorative treatment. Learn more about Align Technology and our products: www.aligntech.com www.invisalign.com www.itero.com www.exocad.com
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at stryker.com and careers.stryker.com. Facts: ● 2024 Sales: $22.6 billion ● Industry: Medical Instruments & Supplies ● Employees: 53,000 worldwide ● 44+ Manufacturing and R&D Locations Worldwide ● $1.5 billion spent on research and development in 2024 ● ~14,200 patents owned globally in 2024 ● Products sold in ~75 countries ● Fortune 500 Company ● 9 consecutive years as one a World's Best Workplace Stryker’s social media community guidelines: https://www.stryker.com/content/m/legal/social-media-community-guidelines/en/index.html Notice Regarding Employee Conduct on Facebook/LinkedIn Meta/LinkedIn does not permit employers to verify or validate “employees” in the (META: “Works at” LinkedIn: “Experience”) section of users’ profiles. Please be aware that the views expressed by individuals on their personal accounts and do not necessarily represent the views of our company. If you encounter any issues with a person claiming to be our employee, we recommend using the “Report Profile” feature. If you’d like to report concerns to our Ethics Hotline, you may do so at: https://app.convercent.com/en-us/LandingPage/b6bb4e84-9fcb-ea11-a974-000d3ab9f296
Henry Schein, Inc. (Nasdaq: HSIC) is a products, services, and technology platforms company for healthcare customers. With more than 25,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional healthcare clinics, as well as other alternate care sites. Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our distribution centers. A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 34 countries and territories. The Company's sales reached $13.2 billion in 2025, and have grown at a compound annual rate of approximately 11.0 percent since Henry Schein became a public company in 1995.
Olympus is passionate about creating customer-driven solutions for the medical industry. For more than 100 years, Olympus has focused on making people’s lives healthier, safer and more fulfilling by helping detect, prevent, and treat disease, furthering scientific research, and ensuring public safety. Olympus is headquartered in Tokyo, Japan, with more than 31,000 employees worldwide in nearly 40 countries and regions.
Edwards Lifesciences (NYSE: EW), is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. We thrive on discovery and expanding the boundaries of medical technology, serving patients in 100+ countries, with the help of our employees in areas including Clinical Affairs, Quality Engineering, Research & Development, Regulatory Affairs, Sales & Marketing, corporate functions and more. Contact Us We want to hear from you and engage in meaningful discussions. However, please note that we are not equipped to provide customer, candidate, or technical support through this platform. If you require assistance from those teams, please find their contact information here: https://www.edwards.com/aboutus/contactus If you’re a patient in need of medical advice, please contact your healthcare provider directly. We reserve the right to remove any comments that are off-topic, repetitive, or include hate speech, profanity, or offensive language. Additionally, we will not engage in discussions about competitor products, off-label use of Edwards products, or unsubstantiated/misleading claims that could cause harm. All Terms and Conditions of LinkedIn apply. For the Edwards Lifesciences privacy policy, visit https://www.edwards.com/legal/privacypolicy.
Latest updates, reports, and threat intel affecting the global network.
Danaher anticipates a strong 2026 due to its diagnostic portfolio being in highly attractive areas such as molecular testing, pathology and...
Jai Shankar Krishnan Zetwerk: Krishnan brings 30+ years of leadership across manufacturing, supply chain, FMCG, pharma, life sciences and...
Urban areas in states like New South Wales and Victoria lead the market, bolstered by strong infrastructure and investment in cutting-edge...
The HbA1c testing market presents opportunities driven by rising Type 2 diabetes cases and advancements in testing technologies.
Stock Price & Recent Moves: Danaher's stock (NYSE: DHR) trades around $208 per share as of October 21, 2025. The price is up roughly 8% in...
The Whittier Daily News is the local news source for Whittier, Montebello, La Habra, Pico Rivera and more, providing breaking news, sports,...
Danaher Corporation's DHR Diagnostics segment continues to contribute steadily to its overall performance. The segment's core revenues...
The United States Drug Abuse Testing Market is projected to grow significantly, reaching US$ 3.71 billion by 2033, up from US$ 2 billion in...
The STD Diagnostic Market is projected to reach $17.93 billion by 2033, growing from $9.82 billion in 2024 at a CAGR of 6.92% during...
A flaw was found in DPDK lib/vhost. Missing length validation before reading command_data in the virtio-net control-queue handler can cause an out-of-bounds read and a host process crash.
Maravel, a PHP framework oriented towards dependency injection, prior to version 10.74.0 has a high-severity Token Replay Vulnerability arising from a structural lifecycle mismatch between stateless token validation engines and high-performance relational caching layers. Any application with low cache memory that causes premature eviction to free up memory and applications running macropay-solutions/maravel-framework that utilize tymon/jwt-auth for API token authentication and blacklist management or any other package that does the same may be affected. This architectural risk might also impact native Laravel applications utilizing cache tags under specific volatile or eviction-capped environments. tymon/jwt-auth automatically probes for cache tag support. If found, it forcefully wraps 14-day token blacklist entries (jti) inside a relational tymon.jwt tag. In environments where the O(1) Atomic Lazy Eviction model is active — either natively inside Maravel-Framework v20.x or manually backported into v10.x via the explicit DI container singletons provided in PR #104 (App\Cache\TaggedCache and App\Cache\TagSet) — a strict global tracking ceiling (Container::TAGGED_CACHE_TTL_CAP_SECONDS) of 7,200 seconds (2 hours) is enforced to secure the system against memory index bloat. This ceiling forcefully truncates the 14-day blacklist lifespan down to a maximum of 2 hours, after which individual tracking keys naturally expire and disappear from the active cache window. Furthermore, because the optimized engine implements a generational version matrix to achieve O(1) flush speeds, any programmatic or manual invocation of a tag flush or reset (e.g., Cache::tags([...])->flush()) instantly bumps the internal atomic master version pointer. This shifts the computed cryptographic composite hash (sha1($this->tags->getNamespace())) for all overlapping components, rendering the entire existing index immediately unreachable. Consequently, through either natural 2-hour expiration or an intervening tag flush execution (like the cache naturally cleaning old values to free up memory), the invalidation state records are entirely wiped out. Because the tokens' physical cryptographic signatures remain structurally valid for up to 14 days, stolen, hijacked, or legitimately logged-out tokens are instantly and silently resurrected across the entire API gateway, leaving the application critically vulnerable to widespread Token Replay Attacks. Because this issue is caused by an upstream architectural assumption within the tymon/jwt-auth package rather than a core defect inside the framework, there is no direct framework version upgrade that can safely bypass this lifecycle collision without breaking business cache recycling bounds. Maravel version 10.74.0 introduced a way to backport the new fixed tagged cache from 20.x into 10.x by resolving TagSet and TaggedCache from DI, which is how this latent architectural lifecycle vulnerability was discovered. Users must apply the decoupled configuration workaround outlined below. As a workaround, make sure that cache memory size does not generate early natural evictions from cache to free up space, deleting blacklisted jwt ids before they expire. Applications must decouple flat authentication vectors from the relational tagging subsystem. This forces token identifiers to write directly to the primary cache keyspace as flat, un-tagged key-value pairs where they securely retain their unclipped 14-day lifecycle.
Sylius is an Open Source eCommerce Framework on Symfony. Starting in version 2.0.0 and prior to version 2.0.18, 2.1.15, and 2.2.6, the `GET /api/v2/shop/payment-requests/{hash}` and `PUT /api/v2/shop/payment-requests/{hash}` endpoints look up the payment request solely by the hash from the URL. No ownership check is performed against the authenticated customer or the underlying order. An attacker who obtains a payment request hash can read the payment request and, through the `payment` IRI in the response, recover the underlying order's `tokenValue` (which itself grants access to the full order, items, addresses, customer email, totals); and/or update the payment request payload (e.g. `target_path`, `after_path`). These fields are used by the front-end controller to redirect the user after the payment, so an attacker can flip them to an attacker-controlled URL and intercept the buyer. The hash is a UUID, so it has to be obtained out-of-band (logs, shared links, referrer headers, a co-located client), but once it is known no other credential is required, neither authentication nor knowledge of the order token. The creation endpoint `POST /api/v2/shop/orders/{tokenValue}/payment-requests` shares the same flaw: it resolves the target order solely from the `tokenValue` in the URL without verifying that the caller owns the order. The issue is fixed in versions 2.0.18, 2.1.15, and 2.2.6. As a workaround, add a query extension that filters the `GET` operation; decorate the `PUT` state provider, guard the `POST` creation endpoint with a command-bus middleware, and wire the services.
Sylius is an Open Source eCommerce Framework on Symfony. Starting in version 2.0.0 and prior to version 2.0.18, 2.1.15, and 2.2.6, an authorization bypass vulnerability exists in the shop account API. The `PATCH /api/v2/shop/account/orders/{tokenValue}/payments/{paymentId}` endpoint, used by an authenticated shop customer to change the payment method of an order that has been placed but not yet paid (state `STATE_NEW`), does not validate that the chosen payment method is enabled for the order's channel. The equivalent checkout endpoint (`PATCH /api/v2/shop/orders/{tokenValue}/payments/{paymentId}`) correctly rejects out-of-channel payment methods with `HTTP 422`; the account endpoint silently accepts them and returns `HTTP 200`. An authenticated customer can therefore assign any globally enabled payment method to their own placed order, including methods that the store operator has explicitly excluded from that channel. The issue is fixed in versions: 2.0.18, 2.1.15, 2.2.6 and above. As a workaround, decorate the `Sylius\Bundle\ApiBundle\Changer\PaymentMethodChangerInterface` service in the application.
Sylius is an Open Source eCommerce Framework on Symfony. Versions 2.0.0 through 2.0.17, 2.1.0 through 2.1.14, and 2.2.0 through 2.2.5 contain an improper workflow enforcement vulnerability in the cart `FormComponent`. When an order is completed while its cart page remains open, the stale LiveComponent does not detect the order’s changed state and continues to permit cart actions, allowing an authenticated customer to modify or permanently delete an already completed order. Versions 2.0.18, 2.1.15, and 2.2.6 contain a patch. As a workaround, deployments can copy the patched `FormComponent` into the application's `src/` directory and override the `sylius_shop.twig.component.cart.form` service definition to use that class.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.